Maynard Um
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) Misses Q1 EPS by 17c
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) PT Raised to $44 at Wedbush
-
-
-
-
-
-
-
Guggenheim Reiterates Buy rating and Best Idea on Travere Therapeutics (TVTX)
-
-
-
-
-
-
-
Jefferies lists 5 biotech M&A candidates for 2026
-
-
-
-
-
-
-
Jefferies on Travere Therapeutics (TVTX): 'AdCom Cancellation Clear Positive In Our View Setting Stage For Likely Approval'
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) Tops Q2 EPS by 16c
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) Announces FDA Acceptance of sNDA for FILSPARI in FSGS
-
415,794 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

